Characterization of four new mouse cytochrome P450 enzymes of the CYP2J subfamily

Drug Metabolism and Disposition

Volumn 41, Issue 4, 2013, Pages 763-773

  Graves, Joan P ^a   Edin, Matthew L ^a   Bradbury, J Alyce ^a   Gruzdev, Artiom ^a   Cheng, Jennifer ^a   Lih, Fred B ^a   Masinde, Tiwanda A ^a   Qu, Wei ^a   Clayton, Natasha P ^a   Morrison, James P ^b   Tomer, Kenneth B ^a   Zeldin, Darryl C ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 2J; CYTOCHROME P450 2J11; CYTOCHROME P450 2J12; CYTOCHROME P450 2J13; CYTOCHROME P450 2J8; EPOXIDE DERIVATIVE; HYDROXY DERIVATIVE; ISOPROTEIN; LINOLEIC ACID; MESSENGER RNA; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; FEMALE; GENETIC CODE; HEART; HEART MUSCLE CELL; INSECT CELL; KIDNEY; LIPID METABOLISM; LIVER; MALE; MOLECULAR PROBE; MOUSE; NEUROPIL; NONHUMAN; OPEN READING FRAME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; SEQUENCE HOMOLOGY; TISSUE DISTRIBUTION;

AMINO ACID SEQUENCE; ANIMALS; ARACHIDONIC ACID; BRAIN; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION; ISOENZYMES; KIDNEY; LINOLEIC ACID; LIVER; MICE; MOLECULAR SEQUENCE DATA; MYOCARDIUM;

HEXAPODA;

EID: 84875871767     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.049429     Document Type: Article

References (48)

1. Athirakul K, Bradbury JA, Graves JP, DeGraff LM, Ma J, Zhao Y, Couse JF, Quigley R, Harder DR, and Zhao X, et al. (2008) Increased blood pressure in mice lacking cytochrome P450 2J5. FASEB J 22:4096-4108.
2. Bylund J, Kunz T, Valmsen K, and Oliw EH (1998) Cytochromes P450 with bisallylic hydroxylation activity on arachidonic and linoleic acids studied with human recombinant enzymes and with human and rat liver microsomes. J Pharmacol Exp Ther 284: 51-60.
3. Campbell WB, Gebremedhin D, Pratt PF, and Harder DR (1996) Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78:415-423.
4. Campbell WB and Harder DR (1999) Endothelium-derived hyperpolarizing factors and vascular cytochrome P450 metabolites of arachidonic acid in the regulation of tone. Circ Res 84: 484-488.
5. Capdevila JH (2007) Regulation of ion transport and blood pressure by cytochrome p450 monooxygenases. Curr Opin Nephrol Hypertens 16:465-470.
6. Capdevila JH, Falck JR, and Harris RC (2000) Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 41:163-181.
7. Catella F, Lawson JA, Fitzgerald DJ, and FitzGerald GA (1990) Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy-induced hypertension. Proc Natl Acad Sci USA 87:5893-5897.
8. DeLozier TC, Tsao CC, Coulter SJ, Foley J, Bradbury JA, Zeldin DC, and Goldstein JA (2004) CYP2C44, a new murine CYP2C that metabolizes arachidonic acid to unique stereospecific products. J Pharmacol Exp Ther 310:845-854.
9. Edin ML, Wang Z, Bradbury JA, Graves JP, Lih FB, DeGraff LM, Foley JF, Torphy R, Ronnekleiv OK, and Tomer KB, et al. (2011) Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart. FASEB J 25:3436-3447.
10. Falck JR, Manna S, Moltz J, Chacos N, and Capdevila J (1983) Epoxyeicosatrienoic acids stimulate glucagon and insulin release from isolated rat pancreatic islets. Biochem Biophys Res Commun 114:743-749.
11. Fidelis P, Wilson L, Thomas K, Villalobos M, and Oyekan AO (2010) Renal function and vasomotor activity in mice lacking the Cyp4a14 gene. Exp Biol Med (Maywood) 235: 1365-1374.
12. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, and Busse R (1999) Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401:493-497.
13. Fleming I (2001) Cytochrome p450 and vascular homeostasis. Circ Res 89:753-762.
14. Gotoh O (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267: 83-90.
15. Holla VR, Makita K, Zaphiropoulos PG, and Capdevila JH (1999) The kidney cytochrome P-450 2C23 arachidonic acid epoxygenase is upregulated during dietary salt loading. J Clin Invest 104:751-760.
16. Kikuta Y, Sogawa K, Haniu M, Kinosaki M, Kusunose E, Nojima Y, Yamamoto S, Ichihara K, Kusunose M, and Fujii-Kuriyama Y (1991) A novel species of cytochrome P-450 (P-450ib) specific for the small intestine of rabbits. cDNA cloning and its expression in COS cells. J Biol Chem 266:17821-17825.
17. Kroetz DL and Zeldin DC (2002) Cytochrome P450 pathways of arachidonic acid metabolism. Curr Opin Lipidol 13:273-283.
18. Larsen BT, Miura H, Hatoum OA, Campbell WB, Hammock BD, Zeldin DC, Falck JR, and Gutterman DD (2006) Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol 290:H491-H499.
19. Lee JP, Yang SH, Lee HY, Kim B, Cho JY, Paik JH, Oh YJ, Kim DK, Lim CS, and Kim YS (2012) Soluble epoxide hydrolase activity determines the severity of ischemia-reperfusion injury in kidney. PLoS ONE 7:e37075.
20. Luo G, Zeldin DC, Blaisdell JA, Hodgson E, and Goldstein JA (1998) Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid. Arch Biochem Biophys 357: 45-57.
21. Ma J, Bradbury JA, King L, Maronpot R, Davis LS, Breyer MD, and Zeldin DC (2002) Molecular cloning and characterization of mouse CYP2J6, an unstable cytochrome P450 isoform. Biochem Pharmacol 64:1447-1460.
22. Ma J, Qu W, Scarborough PE, Tomer KB, Moomaw CR, Maronpot R, Davis LS, Breyer MD, and Zeldin DC (1999) Molecular cloning, enzymatic characterization, developmental expression, and cellular localization of a mouse cytochrome P450 highly expressed in kidney. J Biol Chem 274:17777-17788.
23. Ma J, Ramachandran S, Fiedorek FT, Jr, and Zeldin DC (1998) Mapping of the CYP2J cytochrome P450 genes to human chromosome 1 and mouse chromosome 4. Genomics 49: 152-155.
24. Moran JH, Mitchell LA, Bradbury JA, Qu W, Zeldin DC, Schnellmann RG, and Grant DF (2000) Analysis of the cytotoxic properties of linoleic acid metabolites produced by renal and hepatic P450s. Toxicol Appl Pharmacol 168:268-279.
25. Nebert DW and Russell DW (2002) Clinical importance of the cytochromes P450. Lancet 360: 1155-1162.
26. Nelson DR (2009) The cytochrome p450 homepage. Hum Genomics 4:59-65.
27. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, and Estabrook RW, et al. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6: 1-42.
28. Nelson DR, Zeldin DC, Hoffman SMG, Maltais LJ, Wain HM, and Nebert DW (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1-18.
29. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, and Liao JK (1999) Antiinflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285: 1276-1279.
30. Node K, Ruan XL, Dai J, Yang SX, Graham L, Zeldin DC, and Liao JK (2001) Activation of Ga S mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem 276:15983-15989.
31. Omata K, Abe K, Sheu HL, Yoshida K, Tsutsumi E, Yoshinaga K, Abraham NG, and Laniado-Schwartzman M (1992) Roles of renal cytochrome P450-dependent arachidonic acid metabolites in hypertension. Tohoku J Exp Med 166:93-106.
32. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J Biol Chem 239:2379-2385.
33. Oyekan AO, Youseff T, Fulton D, Quilley J, and McGiff JC (1999) Renal cytochrome P450 omega-hydroxylase and epoxygenase activity are differentially modified by nitric oxide and sodium chloride. J Clin Invest 104:1131-1137.
34. Qu W, Bradbury JA, Tsao CC, Maronpot R, Harry GJ, Parker CE, Davis LS, Breyer MD, Waalkes MP, and Falck JR, et al. (2001) Cytochrome P450 CYP2J9, a new mouse arachidonic acid omega-1 hydroxylase predominantly expressed in brain. J Biol Chem 276: 25467-25479.
35. + channels and p42/p44 MAPK pathway. Circ Res 95:506-514.
36. Seubert JM, Sinal CJ, Graves J, DeGraff LM, Bradbury JA, Lee CR, Goralski K, Carey MA, Luria A, and Newman JW, et al. (2006) Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res 99:442-450.
37. Seubert JM, Zeldin DC, Nithipatikom K, and Gross GJ (2007) Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat 82:50-59.
38. Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR, Node K, Börgel J, Mügge A, and Lindpaintner K, et al. (2004) Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 110:2132-2136.
39. Townsley MI, Morisseau C, Hammock B, and King JA (2010) Impact of epoxyeicosatrienoic acids in lung ischemia-reperfusion injury. Microcirculation 17:137-146.
40. Wang H, Zhao Y, Bradbury JA, Graves JP, Foley J, Blaisdell JA, Goldstein JA, and Zeldin DC (2004) Cloning, expression, and characterization of three new mouse cytochrome p450 enzymes and partial characterization of their fatty acid oxidation activities. Mol Pharmacol 65: 1148-1158.
41. Wang Y, Wei X, Xiao X, Hui R, Card JW, Carey MA, Wang DW, and Zeldin DC (2005) Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J Pharmacol Exp Ther 314:522-532.
42. Wu S, Chen W, Murphy E, Gabel S, Tomer KB, Foley J, Steenbergen C, Falck JR, Moomaw CR, and Zeldin DC (1997) Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 272:12551-12559.
43. Wu S, Moomaw CR, Tomer KB, Falck JR, and Zeldin DC (1996) Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271:3460-3468.
44. Zeldin DC, Foley J, Ma J, Boyle JE, Pascual JM, Moomaw CR, Tomer KB, Steenbergen C, and Wu S (1996) CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance. Mol Pharmacol 50:1111-1117.
45. Zeldin DC, Wei S, Falck JR, Hammock BD, Snapper JR, and Capdevila JH (1995) Metabolism of epoxyeicosatrienoic acids by cytosolic epoxide hydrolase: substrate structural determinants of asymmetric catalysis. Arch Biochem Biophys 316:443-451.
46. Zhang QY, Ding X, and Kaminsky LS (1997) CDNA cloning, heterologous expression, and characterization of rat intestinal CYP2J4. Arch Biochem Biophys 340:270-278.
47. Zhang W, Otsuka T, Sugo N, Ardeshiri A, Alhadid YK, Iliff JJ, DeBarber AE, Koop DR, and Alkayed NJ (2008) Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia. Stroke 39:2073-2078.
48. Zou AP, Drummond HA, and Roman RJ (1996) Role of 20-HETE in elevating loop chloride reabsorption in Dahl SS/Jr rats. Hypertension 27:631-635.